Qiao Kun, Huang Qiongmei, Sun Tongtong, Chen Bei, Huang Wenmei, Su Yongchang, Lin Hetong, Liu Zhiyu
Engineering Research Center of Fujian and Taiwan Characteristic Marine Food Processing and Nutrition and Health, Ministry of Education, College of Food Science, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
Key Laboratory of Cultivation and High-Value Utilization of Marine Organisms in Fujian Province, National and Local Joint Engineering Research Center for Marine Biological Seed Industry Technology, Fisheries Research Institute of Fujian, Xiamen 361013, China.
Nutrients. 2024 Dec 12;16(24):4301. doi: 10.3390/nu16244301.
Marine-derived foods, often called blue foods, are promising sustainable alternatives to conventional food sources owing to their abundant amino acids and high protein content. Current treatments for hyperuricemia, a chronic condition attributed to purine metabolism disorders, are associated with various side effects. Novel peptide xanthine oxidase inhibitors have been discovered in the hydrolyzed products of marine fish and invertebrate proteins, which have demonstrated promising therapeutic potential by reducing uric acid levels in vitro and in vivo. This review explores the potential therapeutic effects of xanthine oxidase inhibitors derived from marine fish and invertebrates, summarizes the methods for extracting bioactive peptides from marine organisms, and emphasizes the impact of different proteases on the structure-activity relationship of bioactive peptides. The hypouricemic effects of these bioactive peptides warrant further verification. There is consensus on the in vitro chemical methods used to verify the xanthine oxidase inhibitory effects of these peptides. Considering several cell and animal model development strategies, this review summarizes several highly recognized modeling methods, proposes strategies to improve the bioavailability of bioactive peptides, and advocates for a diversified evaluation system. Although the screening and evaluation methods for antihyperuricemic peptides have been shown to be feasible across numerous studies, they are not optimal. This review examines the deficiencies in bioavailability, synthesis efficiency, and evaluation mechanisms in terms of their future development and proposes potential solutions to address these issues. This review provides a novel perspective for the exploration and application of marine-derived hypouricemic bioactive peptides.
海洋源食物，通常被称为蓝色食物，由于其富含氨基酸和高蛋白含量，是传统食物来源有前景的可持续替代品。高尿酸血症是一种归因于嘌呤代谢紊乱的慢性疾病，目前针对该疾病的治疗方法存在各种副作用。在海鱼和无脊椎动物蛋白质的水解产物中发现了新型肽类黄嘌呤氧化酶抑制剂，这些抑制剂在体外和体内均通过降低尿酸水平显示出有前景的治疗潜力。本综述探讨了源自海鱼和无脊椎动物的黄嘌呤氧化酶抑制剂的潜在治疗作用，总结了从海洋生物中提取生物活性肽的方法，并强调了不同蛋白酶对生物活性肽结构-活性关系的影响。这些生物活性肽的降尿酸作用有待进一步验证。对于用于验证这些肽的黄嘌呤氧化酶抑制作用的体外化学方法已达成共识。考虑到几种细胞和动物模型开发策略，本综述总结了几种高度认可的建模方法，提出了提高生物活性肽生物利用度的策略，并倡导建立多元化的评估系统。尽管抗高尿酸血症肽的筛选和评估方法在众多研究中已被证明是可行的，但并非最优。本综述从其未来发展的角度审视了生物利用度、合成效率和评估机制方面的不足，并提出了解决这些问题的潜在方案。本综述为海洋源降尿酸生物活性肽的探索和应用提供了新的视角。
